HYBRID COOPERATIVE COMPLEXES OF HYALURONIC ACID

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 13/820,838

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.

Claims (37)

1 . Stable, hybrid cooperative L/H-HA complexes prepared by submitting to thermal treatment, at temperature comprised between 80° and 160°, solutions containing simultaneously L-HA hyaluronic acid or hyaluronans and H-HA hyaluronic acid or hyaluronans wherein the molecular weight of L-HA is comprised between 1×10 4 to 1×10 6 Da and that of H-HA is given by the formula MW H-HA ≧ MWL-HA /0.9.

2 . Stable complexes according to claim 1 wherein said temperature is comprised between 100° and 120° C.

3 . Hybrid cooperative complexes according to claim 1 , wherein H-HA and L-HA are present in relative quantities comprised between 0.1 and 10.

4 . L/H-HA complexes according to claim 1 having a viscosity from 1.1 to 200-fold less than that of a solution containing the H-HA hyaluronic acid alone used for forming the complex.

5 . L/H-HA complexes according to claim 4 , wherein other chemical species in addition to solvent and hyaluronic acid are also present in the solution.

6 . L/H-HA complexes according to claim 1 , wherein the solvent used is water.

7 . L/H-HA complexes according to claim 1 , wherein the thermal treatment is carried out in autoclave.

8 . L/H-HA complexes according to claim 1 , wherein the thermal treatment includes keeping the sample at the maximal temperature for times which are from 10 seconds to 2 hrs.

9 . L/H-HA complexes according to claim 8 , wherein the thermal treatment includes reaching the maximal temperature over times from 1 min to 1 h.

10 . L/H-HA complexes according to claim 8 wherein the thermal treatment includes cooling the solution, after exposure at the maximal temperature, over times from 1 min to 1 h.

11 . L/H-HA complexes according to claim 1 , prepared in the solid state by precipitation of the solutions containing them.

12 . L/H-HA complexes according to claim 11 , wherein the precipitation is obtained by adding a compound miscible with the solution and acting as a non-solvent for the complex.

13 . L/H-HA complexes according to claim 12 , wherein the non-solvent compound for the complex is a water-miscible organic solvent, selected from the group consisting of acetone, methanol, ethanol, propanol, isopropanol and butanol.

14 . L/H-HA complexes according to claim 1 , prepared by removing the solvent by means of vacuum evaporation, spray-drying or freeze-drying in the dry state.

15 . Hybrid cooperative complexes according to claim 1 , wherein the low molecular weight hyaluronic acid is replaced by other low molecular weight polysaccharides, such as chondroitin, chondroitin sulphate, dextrins, cyclodextrins, dextrans.

16 . Hybrid cooperative complexes according to claim 15 wherein by low molecular weight of polysaccharides is meant less than one million of Da.

17 . Method of treating patients in need thereof with hybrid cooperative complexes of claim 1 comprising:

administering to said patients said hybrid cooperative complexes as a replacement for high molecular weight hyaluronic acid in all clinical treatments based on said high weight hyaluronic acid and

treating said patients in need.

18 . Method for intradermal bio-revitalizing treatment with hybrid cooperative complexes according to claim 1 comprising: